Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

NVS has decided to license a novel capsid generated from Voyager's TRACER platform for use in a gene therapy program against an undisclosed rare neurologic disease target.

Novartis to License VYGR's Capsid for Gene Therapy in Neurology

Goldman Sachs has downgraded Novartis AG NVS, citing “limited value driving innovation catalysts in the near term.”

Goldman Sachs Shifts Stance On Novartis, Cites Lack Of Near-Term Catalysts

Novartis (NVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Novartis (NVS) Upgraded to Buy: Here's What You Should Know

NVS' late-stage study meets its primary endpoints, demonstrating the superiority of Leqvio monotherapy over both placebo and ezetimibe in LDL-C reduction.

Novartis' Cholesterol Drug Meets Primary Goals in Late-Stage Study

RALEIGH, N.C.--(BUSINESS WIRE)--Lindy Biosciences, a pioneering biotechnology company specializing in innovative drug formulation and delivery technologies, today announced a multi-target exclusive global licensing agreement and strategic collaboration with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE: NVS), an innovative medicines company. The collaboration will focus on transitioning select innovative medicines from the Novartis portfolio to convenient, self-administered subcutaneous.

Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery Innovation

Basel, August 28, 2024 – Novartis announced today positive topline results from twice-yearly* Leqvio® (inclisiran) in the Phase III V-MONO study, which met its primary endpoints. Leqvio monotherapy achieved clinically meaningful and statistically significant low-density lipoprotein cholesterol (LDL-C) lowering versus both placebo and ezetimibe in patients who were at low or moderate risk of developing atherosclerotic cardiovascular disease (ASCVD) and not receiving lipid-lowering therapy1.

Novartis twice-yearly* Leqvio® demonstrated clinically meaningful, statistically significant LDL-C lowering as a monotherapy in patients at low or moderate ASCVD risk

Siemens Healthineers AG

Siemens Healthineers will pay more than 200 million euros ($223.8 million) to acquire the diagnostic arm of Advanced Accelerator Applications, owned by Novartis , the Financial Times reported on Saturday.

Siemens Healthineers to buy Novartis unit for over $223 million, FT reports

VANCOUVER--(BUSINESS WIRE)--Borealis Biosciences, a next-generation RNA medicines company, today emerged from stealth with $150 million in combined Series A financing from founding investor Versant Ventures and Novartis AG, as well as committed strategic research collaboration funding from Novartis. Despite recent advances for patients with IgA nephropathy, many other forms of highly prevalent kidney disease remain unaddressed. The understanding of patient subpopulations and distinct underlying.

Versant Ventures and Novartis Launch Borealis Biosciences With $150 Million in Funding

AstraZeneca

GlaxoSmithKline

Johnson & Johnson

Eli Lilly

Merck

Novo Nordisk

Pfizer

Roche Holding AG

Sanofi

In the ever-evolving pharmaceutical landscape, financial stability and business resilience are crucial for long-term success. S&P Global, a leading financial information firm, recently released a comprehensive report evaluating the world's top pharmaceutical companies based on their business and financial risk profiles.

Top 10 pharmaceutical companies in 2024: S&P Global's latest ratings and rankings

DexCom

Despite DexCom's recent challenges, it still has ample growth opportunities. Novartis is a reliable dividend payer that recently changed its business for the better.

2 Unstoppable Healthcare Stocks to Buy Right Now With Less Than $200

Novartis' (NVS) efforts to ward off generic competition for its top cardiovascular drug, Entresto, face a setback.

Novartis' (NVS) Motion to Block Entresto Generic Denied: What's Next?

Novartis failed to convince a Delaware federal court to block generic drugmaker MSN Pharmaceuticals from launching its own version of Novartis' blockbuster heart-failure drug Entresto, according to a court decision issued on Monday.

Novartis loses initial bid to block generic of best-selling heart drug

Becton, Dickinson and Co.

Clorox

Diageo

Fortis

Kimberly-Clark

McDonald's

McCormick

PepsiCo

Market volatility recently hit the 3rd highest levels ever recorded, and extreme fear grips Wall Street. The yen carry trade unwind is likely not over yet; US recession risks remain elevated, and the market decline might still have another 8%. Dividend aristocrats are down just 0.9% in this downturn, and many aristocrats are up modestly.

10 High-Yield Dividend Aristocrats That Could Be Perfect For What's Coming Next

Fabhalta achieved a 44% proteinuria reduction from baseline in Phase III APPLAUSE-IgAN interim analysis, compared with 9% in placebo arm, demonstrating a clinically meaningful reduction of 38% vs. placebo (p

Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)

The U.S. Food and Drug Administration has approved the use of Novartis' drug to treat patients with a type of kidney disease, the health regulator's website showed on Wednesday.

US FDA approves Novartis' kidney disease drug

Viatris

Novartis and Viatris were hit with a federal lawsuit in Maryland on Monday by the family of a woman whose tissue cells were taken from her body in the 1950s and used to fuel medical research and development.

Novartis, Viatris face new lawsuit over 'HeLa' cell misuse claims

FOSTER CITY, Calif.--(BUSINESS WIRE)--Dren Bio Announces Strategic Collaboration with Novartis to Develop Novel Targeted Myeloid Engagers for Cancer.

Dren Bio Announces Strategic Collaboration with Novartis to Develop Novel Targeted Myeloid Engagers for Cancer

The company continues to deliver strong turnover growth and core margin expansion. Ongoing buyback combined with a juicy dividend yield provides downside protection. Positive contributions from newer drug launches. Novartis raised the 2024 core operating income guidance. Our buy rating is then confirmed.

Novartis: Another Beat, Another Raise

On July 18, Novartis AG released its second-quarter 2024 financial results, which were solid. The company's free cash flow was about $4.62 billion for the second quarter of 2024, up 40% year over year, primarily due to strong sales of its oncology franchise. So, Kisqali sales amounted to $717 million for the three months ended June 30, 2024, an increase of 45.4% year-on-year.

Why Novartis Deserves Your Attention After Q2 2024 Results

Novartis NYSE: NVS is the seventh largest pharmaceutical company in the world, and is based in Switzerland. The firm reported Q2 2024 financial results on Jul. 18, 2024.

Pharma Leader Beats on Earnings, But Shares Fall

Drugmaker Novartis' second-quarter results were better than expected. Profit guidance for the remainder of the year was also raised.

Why Novartis Stock Is Down Today Despite Topping Q2 Estimates

Novartis AG (NYSE:NVS ) Q2 2024 Earnings Conference Call July 18, 2024 8:00 AM ET Company Participants Sloan Simpson - Head of IR Vas Narasimhan - CEO Harry Kirsch - CFO Conference Call Participants Emily Field - Barclays Florent Cespedes - Bernstein Emmanuel Papadakis - Deutsche Bank Richard Parkes - BNP Paribas Graham Parry - Bank of America James Quigley - Goldman Sachs Mark Purcell - Morgan Stanley Richard Vosser - JPMorgan Peter Welford - Jefferies Peter Verdult - Citi Kerry Holford - Berenberg Seamus Fernandez - Guggenheim Securities Rajesh Kumar - HSBC Jo Walton - UBS Tim Anderson - Wolfe Research Operator Good morning and good afternoon, and welcome to the Novartis Q2 2024 Results Release Conference Call and Live Webcast. Please note that during the presentation all participants will be in a listen-only mode and the conference is being recorded.

Novartis AG (NVS) Q2 2024 Earnings Call Transcript

Novartis (NVS) American depositary receipts (ADRs) slipped Thursday even though the pharmaceutical giant beat second-quarter earnings expectations and raised its full-year core operating income guidance.

Novartis Falls Despite Earnings Beat, Guidance Raise

The headline numbers for Novartis (NVS) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Novartis (NVS) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Abbott Labs

Healthcare stocks to check out in the stock market right now.

2 Healthcare Stocks For Your Mid-July 2024 Watchlist

News for Novartis Stock (NVS)